Roche Selects Two Genmab Antibodies as Clinical Candidates

Roche Selects Two Genmab Antibodies as Clinical Candidates


COPENHAGEN, Denmark, March 19 /PRNewswire/ --     


    - Summary: Roche has selected two Genmab antibodies as clinical 
candidates for two different disease areas. 



    Genmab A/S (CSE: GEN) announced today Roche has selected two Genmab 
antibodies as candidates for clinical development.  The antibodies, developed 
under a collaboration between Roche and Genmab which began in May 2001, are 
each designed to target a different disease area. 



    "The selection of these antibodies as clinical candidates underlines 
Genmab's skill in producing antibody product candidates as well as Roche's 
ability to identify valid disease targets," said Lisa N. Drakeman, Ph.D., 
Chief Executive Officer of Genmab. "Our partnership with Roche continues to 
be fruitful." 



    Under the agreement, Genmab utilises its broad antibody expertise and 
development capabilities to create human antibodies to a broad range of 
disease targets identified by Roche.  Roche has a proven successful track 
record in developing biologicals as innovative new products.  Genmab receives 
milestone and royalty payments based on successful products.  In certain 
circumstances, Genmab may obtain rights to develop products based on disease 
targets identified by Roche.  If all goals are reached, the value of the 
collaboration to Genmab could be $100 million, plus royalties. 
  


    Conference Call 



    Genmab's Management will hold a conference call to discuss the news 
today, Friday, March 19, at  
  


    3:00 pm CET 


    2:00 pm GMT 


    9:00 am US Eastern Time 
  


    The dial in numbers are as follows: 
  


    [phone] (in the US) and ask for the Genmab conference call 


    [phone] (outside the US) and ask for the Genmab conference call 
  


    The conference call will be held in English. 
 


    About Genmab A/S 



    Genmab A/S is a biotechnology company that creates and develops human 
antibodies for the treatment of life-threatening and debilitating diseases. 
Genmab has numerous products in development to treat cancer, infectious 
disease, rheumatoid arthritis and other inflammatory conditions, and intends 
to continue assembling a broad portfolio of new therapeutic products. At 
present, Genmab has multiple partnerships to gain access to disease targets 
and develop novel human antibodies including agreements with Roche and Amgen. 
A broad alliance provides Genmab with access to Medarex, Inc.'s array of 
proprietary technologies, including the UltiMAb(TM) platform for the rapid 
creation and development of human antibodies to virtually any disease target. 
Genmab is headquartered in Copenhagen, Denmark and has operations in Utrecht, 
The Netherlands and Princeton, New Jersey in the US. For more information 
about Genmab, visit www.genmab.com. 



    Except for the historical information presented herein, matters discussed 
in this press release are forward-looking statements that are subject to 
certain risks and uncertainties that could cause actual results to differ 
materially from any future results, performance or achievements expressed or 
implied by such statements, e.g. unforeseen exchange rate and interest rate 
fluctuations, delayed or unsuccessful development projects. 



    Statements that are not historical facts, including statements preceded 
by, followed by, or that include the words "believes"; "anticipates"; 
"plans"; "expects"; "estimates"; or similar statements are forward-looking 
statements. Genmab is not under an obligation to up-date statements regarding 
the future following the publication of this release; nor to confirm such 
statements in relation to actual results, unless this is required by law.  
 


    Web site:  http://www.genmab.com


DATASOURCE: Genmab A/S



CONTACT:  Sisse P. Hansen, Investor & Public Relations of Genmab A/S,
[phone], mobile, [phone], or [e-mail]

Copyright